KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $108.6 million.

  • Supernus Pharmaceuticals' Accounts Payables rose 4328.32% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year increase of 4328.32%. This contributed to the annual value of $76.4 million for FY2024, which is 404.3% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Accounts Payables stood at $108.6 million for Q3 2025, which was up 4328.32% from $77.7 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Accounts Payables registered a high of $133.0 million during Q2 2022, and its lowest value of $70.1 million during Q1 2021.
  • For the 5-year period, Supernus Pharmaceuticals' Accounts Payables averaged around $88.9 million, with its median value being $82.6 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Accounts Payables skyrocketed by 11240.19% in 2021, and later crashed by 3756.09% in 2023.
  • Supernus Pharmaceuticals' Accounts Payables (Quarter) stood at $117.7 million in 2021, then decreased by 18.13% to $96.3 million in 2022, then dropped by 17.41% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then skyrocketed by 42.25% to $108.6 million in 2025.
  • Its last three reported values are $108.6 million in Q3 2025, $77.7 million for Q2 2025, and $76.9 million during Q1 2025.